Patents by Inventor John Mcintosh
John Mcintosh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250215464Abstract: The present disclosure provides enzymes derived from the fungi Fusarium oxysporum c8D (“FoPip4H enzymes”) having improved properties as compared to a naturally occurring wild-type enzyme including the capability of hydroxylating certain substituted indanones to provide optically pure 3-hydroxyindanones. Also provided are polynucleotides encoding the FoPip4H enzymes, host cells capable of expressing the FoPip4H enzymes, and processes for using the FoPip4H enzymes to synthesize (R)-4-fluoro-3-hydroxy-7-(methylsulfonyl)-2, 3-dihydro-1H-inden-1-one, a useful intermediate in the synthesis of belzutifan.Type: ApplicationFiled: July 5, 2023Publication date: July 3, 2025Applicant: Merck Sharp & Dohme LLCInventors: Wai Ling Cheung-Lee, Daniel A. DiRocco, Agnieszka Gil, Kaori Hiraga, Jungchul Kim, Joshua Kolev, Birgit Kosjek, Kevin M. Maloney, Nastaran Salehi Marzijarani, John McIntosh, Jonathan P. McMullen, Jeffrey C. Moore, Grant S. Murphy, Weilan Pan, Juan E. Velasquez Velez, Deeptak Verma, Matthew S. Winston, Li Xiao, Victoria Zhang
-
Publication number: 20250151186Abstract: A method of controlling a lighting effect generated by a plurality of participating devices, the plurality of participating devices each having a first side with a controllable light emission module and a second side having a participant input apparatus for a user of the device, the lighting effect being formed by a combination of light emissions from the light emission module of the devices. The method includes determining control of the light emission module of the devices such that between them they generate a lighting effect depending in nature on user inputs via the participant input apparatus of the devices, and controlling the light emission module in accordance with the determined control.Type: ApplicationFiled: January 26, 2023Publication date: May 8, 2025Inventor: John MCINTOSH
-
Publication number: 20240247240Abstract: The present disclosure provides transaminase enzymes having improved properties and are capable of reducing (1S,5R)-6,8-dioxabicyclo[3.2.1]octan-4-one with high selectivity. Also provided are polynucleotides encoding the transaminase enzymes, host cells capable of expressing the transaminase enzymes, and methods of using the transaminase enzymes to synthesize (1S,4R,5R)-6,8-dioxabicyclo[3.2.1]octan-4-amine.Type: ApplicationFiled: May 26, 2022Publication date: July 25, 2024Applicant: MERCK SHARP & DOHME LLCInventors: Karla M. Camacho Soto, Wai Ling Cheung-Lee, Hsing-I Ho, John McIntosh, Grant S. Murphy, Weilan Pan, Christopher K. Prier, Deeptak Verma
-
Publication number: 20240199680Abstract: The present invention relates to efficient processes useful in the preparation of fluorinated cyclic dinucleosides, such as [P(R)]-2?-deoxy-2?-fluoro-5?-O—[(R)-hydroxymercaptophosphinyl]-P-thio-?-D-arabino-adenylyl-(3??5?)-3?-deoxy-3?-fluoroguanosine cyclic nucleotide, which is also known as (2R,5R,7R,8S,10R,12aR,14R,15S,15aR,16R)-7-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-14-(6-amino-9H-purin-9-yl)-15,16-difluoro-2, 10-bis(sulfanyl)octahydro-2H,10H, 12H-2?5,10?5-5,8-methanofuro[3,2-1][1, 3,6,9,11,2,10]pentaoxadiphosphacyclotetradecine-2,10-dione. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.Type: ApplicationFiled: March 28, 2022Publication date: June 20, 2024Applicant: Merck Sharp & Dohme LLCInventors: Chihui An, Patrick S. Fier, Kaori Hiraga, Zhijian Liu, Nicholas M. Marshall, John McIntosh, Steven P. Miller, Jeffrey C. Moore, Grant S. Murphy, Jennifer V. Obligacion, Weilan Pan, Feng Peng, Nastaran Salehi Marzijarani, Matthew S. Winston
-
Publication number: 20240140920Abstract: The present invention relates to efficient synthetic processes useful in the preparation of uridine, which is useful in the production of nucleosides and nucleotides that may be active as antiviral agents, as well as compositions and methods thereof.Type: ApplicationFiled: December 17, 2021Publication date: May 2, 2024Applicant: Merck Sharp & Dohme LLCInventors: Tamas Benkovics, Anna Fryszkowska, Mark A. Huffman, Tetsuji Itoh, Kevin M. Maloney, John McIntosh, Grant S. Murphy
-
Publication number: 20240092818Abstract: The present invention relates to efficient synthetic processes useful in the preparation of antiviral nucleosides, particularly uridine 4-oxime 5?-(2-methylpropanoate) {(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl]oxolan-2-yl}methyl 2-methylpropanoate and pharmaceutically acceptable salts, derivatives, tautomers, isomers, and prodrugs of, which may be active as antiviral agents, as well as compositions and methods thereof. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.Type: ApplicationFiled: December 17, 2021Publication date: March 21, 2024Applicant: Merck Sharp & Dohme LLCInventors: Tamas Benkovics, Patrick S. Fier, Anna Fryszkowska, Mark A. Huffman, Tetsuji Itoh, Jongrock Kong, Peter E. Maligres, Kevin M. Maloney, John McIntosh, Grant S. Murphy, Steven M. Silverman, Hao Yang
-
Publication number: 20240076703Abstract: The present disclosure provides MTR kinase polypeptides having improved properties as compared to a naturally occurring wild-type MTR kinase polypeptide including the capability of phosphorylating D-ribose and 5?-D-isobutyrylribose to give alpha-D-ribose-1-phosphate and alpha 5?-D-isobutyrylribose-1-phosphate. Also provided are polynucleotides encoding the MTR kinase polypeptides, host cells capable of expressing the MTR kinase polypeptides, and methods of using the MTR kinase polypeptides to synthesize alpha-D-ribose-1-phosphate and alpha 5?-D-isobutyrylribose-1-phosphate.Type: ApplicationFiled: December 9, 2021Publication date: March 7, 2024Applicant: Merck Sharp & Dohme LLCInventors: Tamas Benkovics, Hsing-I Ho, John McIntosh, Grant S. Murphy, Weilan Pan, Deeptak Verma, Hao Yang
-
Publication number: 20240010613Abstract: The disclosure provides a novel process and synthetic intermediates for making belzutifan, a HIF-2a inhibitor, useful for the treatment of certain VHL-related indications and cancer.Type: ApplicationFiled: July 3, 2023Publication date: January 11, 2024Applicant: Merck Sharp & Dohme LLCInventors: Daniel A. DiRocco, Jackson Kenai Blender Cahn, Wai Ling Cheung-Lee, Stephanie W. Chun, J. Caleb Hethcox, Heather Claire Johnson, Jungchul Kim, Joshua N. Kolev, Birgit Kosjek, Diane Le, Scott D. McCann, John McIntosh, Jonathan P. McMullen, Jeffrey C. Moore, William Morris, Juan Esteban Velasquez Velez, Matthew S. Winston, Victoria Zhang, Yong-Li Zhong
-
Publication number: 20230174992Abstract: The present disclosure provides ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme including the capability of reducing N-(7-((2S,4R,5R)-4-fluoro-3,3-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-4-oxo-4,7-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)isobutyramide. Also provided are polynucleotides encoding the ketoreductase enzymes, host cells capable of expressing the ketoreductase enzymes, and methods of using the ketoreductase enzymes to synthesize N-(9-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide.Type: ApplicationFiled: May 20, 2021Publication date: June 8, 2023Applicant: Merck Sharp & Dohme LLCInventors: Tamas Benkovics, Karla M. Camacho Soto, John McIntosh, Jeffrey C. Moore, Weilan Pan, Deeptak Verma, Li Xiao
-
Publication number: 20060048697Abstract: A system (10) for monitoring and controlling a fabrication process includes at least a first subsystem (12), a crystallographic analysis subsystem (14), and a second subsystem (16), wherein the first subsystem and second subsystem perform respective fabrication steps on a workpiece. The crystallographic analysis subsystem may be coupled to both the first subsystem and second subsystem. The analysis subsystem acquires crystallographic information from the workpiece after the workpiece undergoes a fabrication step by the first subsystem and then provides information, based on the crystallographic information acquired, for modifying parameters associated with the respective fabrication steps. The system may also include neural networks (24, 28) to adaptively modify, based on historical process data (32), parameters provided to the respective fabrication steps. The analysis subsystem may include a electromagnetic source (61), a detector (66), a processor (67), a controller (68) and a scanning actuator (65).Type: ApplicationFiled: February 24, 2003Publication date: March 9, 2006Inventors: Erik Houge, John Mcintosh, Robert Jones